Skip to main content
SpringerLink
Log in

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam

  • Brief Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

We describe two cystic fibrosis patients infected with pandrug-resistant Burkholderia cepacia complex, with the exception of ceftazidime–avibactam, who received prophylaxis with this antibiotic during lung transplantation. Although both patients had a post-operative relapse of respiratory infection, one with positive blood cultures, ceftazidime–avibactam treatment yielded a favourable outcome. 12 months after transplantation, one patient presented an excellent clinical outcome. However, the other patient died 10 months later due to severe B. cepacia sinusitis with intracranial invasion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99–110.

    Article  PubMed  Google Scholar 

  2. Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73–82.

    Article  PubMed  Google Scholar 

  3. Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.

    Article  PubMed  Google Scholar 

  5. De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Hear lung Transplant. 2010;29:1395–404.

    Article  Google Scholar 

  6. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase combinations. Clin Infect Dis. 2016;63:234–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483–93.

    Article  CAS  PubMed  Google Scholar 

  8. Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol. 2009;47:2607–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic Fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–30.

    Article  CAS  PubMed  Google Scholar 

  10. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Nosotti M, Dell’Amore A, Diso D, Oggionni T, Aliberti S, Study Group for Thoracic Organs Transplantation E, et al. Selection of candidates for lung transplantation: the First Italian Consensus Statement. Transplant Proc. 2017;49:702–6.

    Article  CAS  PubMed  Google Scholar 

  12. Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.

    Article  CAS  PubMed  Google Scholar 

  13. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.

    Article  PubMed  Google Scholar 

  14. Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009;179:257–8.

    Article  PubMed  Google Scholar 

  15. Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.

    Article  CAS  PubMed  Google Scholar 

  16. Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862–9.

    Article  CAS  PubMed  Google Scholar 

  17. Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime–avibactam. Antimicrob Agents Chemother. 2018;62:e02213-17.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73:2270–1.

    Article  CAS  PubMed  Google Scholar 

  19. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne bla KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097–16.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Ibai Los-Arcos received a Rio Hortega contract through the 2016 call for Strategic Action in Health from Instituto de Salud Carlos III of the Spanish Health Ministry for the years 2017–2018. The authors thank Celine Cavallo for English language support.

Funding

This research received no specific Grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, P° Vall d’Hebron 119-129, 08035, Barcelona, Spain

    Ibai Los-Arcos, Oscar Len & Joan Gavaldà

  2. Microbiology Department, Hospital Universitari Vall d’Hebron, P° Vall d’Hebron 119-129, 08035, Barcelona, Spain

    María Teresa Martín-Gómez & Juan José González-López

  3. Lung Transplant Unit, Hospital Universitari Vall d’Hebron, P° Vall d’Hebron 119-129, 08035, Barcelona, Spain

    Berta Saéz-Giménez & Antonio Román

  4. Thoracic Surgery Department, Hospital Universitari Vall d’Hebron, P° Vall d’Hebron 119-129, 08035, Barcelona, Spain

    María Deu

  5. Critical Care Department, Hospital Universitari Vall d’Hebron, P° Vall d’Hebron 119-129, 08035, Barcelona, Spain

    Xavier Nuvials & Ricard Ferrer

  6. Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

    Ibai Los-Arcos, Oscar Len & Joan Gavaldà

Authors
  1. Ibai Los-Arcos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oscar Len
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Teresa Martín-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan José González-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Berta Saéz-Giménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. María Deu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xavier Nuvials
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ricard Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio Román
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Joan Gavaldà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oscar Len.

Ethics declarations

Conflict of interest

I.L. has been a speaker for Pfizer and has received travel support from Gilead, Merck and Novartis. O.L. has received a research grant from Pfizer and has been speaker for Pfizer, Astellas, Novartis and Merck. The rest of the authors declare that they have no conflicts of interest related to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Los-Arcos, I., Len, O., Martín-Gómez, M.T. et al. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam. Infection 47, 289–292 (2019). https://doi.org/10.1007/s15010-018-1261-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-018-1261-y

Keywords

Search

Navigation